Epilepsy and Movement Disorder IST with Epidiolex
Jazz only supports study proposals that have a legitimate scientific purpose and take into account the importance of the study objectives to medical science and patient care and the ability of the study sponsor to deliver a high-quality ethical study. Submission of a proposal does not imply or guarantee approval.
Epidiolex®/Epidyolex® 2025 ARIs
- Outcomes associated with Epidiolex®/Epidyolex® use early in the treatment pathway in epilepsy syndromes
- Impact of Epidiolex®/Epidyolex® on non-seizure outcomes (e.g. cognition, behaviour, mood, sleep, QoL) in neurodevelopmental disorders commonly associated with epilepsy
- Outcomes associated with Epidiolex®/Epidyolex® use for the treatment of broad-spectrum seizure disorders in all age groups (esp adults) and in various seizure types
- Potential modes of action of Epidiolex®/Epidyolex®
- Best practices in Epidiolex®/Epidyolex® use/management
Jazz has a two-stage review process: concept and protocol review. After you submit your concept proposal, our Review Committee will notify you of our decision. If your concept is preliminarily accepted, Jazz will invite you to submit a full protocol within 90 days of the notification.
Please be prepared to provide the following information at the time of your concept submission:
- Primary Investigator information and a current CV
- Study hypothesis, objectives, and endpoints
- Background & rationale
- Study design
- Subject population
- Statistical analysis plan
- Publication plan
- Preliminary budget (a detailed budget will be required at the protocol stage)
- Quantity of product requested (if applicable)
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.